

For immediate release

10 June 2025

**CVS Group plc**  
**("CVS" or the "Company" and, together with its subsidiaries, the "Group")**

**Response to CMA announcement**

Following the announcement by the Competition and Markets Authority ("CMA") this morning, CVS notes their decision to extend the statutory deadline of the market investigation reference in relation to the supply of veterinary services for household pets in the UK, so the CMA can fully consider the responses received from the veterinary industry on proposed remedies.

CVS continues to actively engage with the CMA, providing constructive feedback on transparency measures which we believe will comprehensively address the concerns the CMA has identified. CVS welcomes the CMA's recognition of the importance of proportionality of any interventions and the risk that well-meaning interventions could have unintended consequences for animal welfare, pet owners, vets and veterinary businesses. In that respect, we welcome the CMA's extension to consider their options further.

CVS was among those who gave detailed feedback to the CMA on its remedy package, in which it outlined support for the CMA's focus on transparency and improving communication, but also outlined many aspects of its initial package that CVS believed to be unduly cumbersome for vets and even more critically would not empower consumers to make better choices. CVS also gave the CMA feedback on remedies that it believed would unduly constrain clinical freedom of vets, which must remain sacrosanct.

We are optimistic that the extension will improve the ultimate remedy package and ensure it is proportionate but recognise the impact that the extension will have on our colleagues and other stakeholders, who will be understandably disappointed by the continued uncertainty. We will continue to support our teams through this process and would like to thank them for their ongoing dedication and hard work in the face of the significant challenges brought about by this process.

CVS will continue to collaborate closely with the CMA, as we have done consistently since the CMA first launched its market review on 7 September 2023, over the extended timetable.

**CVS Group plc**  
Richard Fairman, CEO  
Robin Alfonso, CFO  
Paul Higgs, Chief Veterinary Officer

**via Camarco**

**Peel Hunt LLP (Nominated Adviser & Joint Broker)** +44 (0)20 7418 8900  
Christopher Golden / James Steel / Andrew Clark

**Berenberg (Joint Broker)** +44 (0)20 3207 7800  
Toby Flaux / Michael Burke / James Thompson / Milo Bonser

**Camarco (Financial PR)** +44 (0)7961 315 138  
Ginny Pulbrook  
Letaba Rimell  
Tilly Butcher

**About CVS Group plc ([www.cvsukltd.co.uk](http://www.cvsukltd.co.uk))**

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.460 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.9,000 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RSPURVBRVAUNARR